Multiplicom Receives €1.9m Grant
News May 26, 2016
With this grant, Multiplicom will accelerate its development of liquid biopsy based NGS cancer tests that will improve the quality of life of cancer patients.
“We are determined to continue enabling personalized medicine and in this way improve the quality of life of cancer patients. This grant and the support of the Flemish Government will help us to achieve this goal,” explains Dirk Pollet, CEO Multiplicom. “The objective of our funded project is to develop innovative and advanced non-invasive genetic tests that allow the selection of the best available treatment.”
Jurgen Del Favero, CTO at Multiplicom continues: “The development of advanced tools and tests will greatly improve the management of cancer patients. It will enable oncologists to more precisely determine specific treatments per patient, monitor treatment outcomes and detect therapy resistance in a cost and time efficient manner.”
For this granted project, Multiplicom will collaborate with the VIB Laboratory of Translational Genetics, Vesalius Research Centre, KULeuven; Division of Gynaecologic Oncology, University Hospital Leuven and Antwerp University Hospital.
Flanders Innovation & Entrepreneurship stimulates growth and innovation by granting financial support to promising companies. Flanders Innovation & Entrepreneurship (Agentschap Innoveren & Ondernemen) is a government agency, charged with implementing the economic, innovation and enterprise policy in Flanders.
Scientists have identified sodium glucose transporter 2 (SGLT2) as a mechanism that lung cancer cells can utilize to obtain glucose, which is key to their survival and promotes tumor growth. The finding provides evidence that SGLT2 may be a novel biomarker that scientists can use to help diagnose precancerous lung lesions and early-stage lung cancers.READ MORE